Last edition
News about "NMPA"
Innovent's DOVBLERON Secures Second NMPA Approval for ROS1-Positive NSCLC
China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON®, a next-generation ROS1 tyrosine kinase inhibitor (TKI).
NMPA | 03/01/2025 | By Abha
Gufic receives approval from NMPA, China for Prilocaine API
Gufic receives approval from NMPA, China for Prilocaine API
NMPA | 19/06/2023 | By Sudeep Soparkar | 350
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy